Pharmaceutical Executive-05-01-2016

Pharm Exec’s 10th annual Brand of the Year is Bristol-Myers Squibb’s Opdivo, which has raced into the lead position in the treatment-shifting immuno-oncology space behind launches in three key cancers-melanoma, lung, and renal.

A conversation with GlaxoSmithKline's US Pharmaceuticals head Jack Bailey.

An “how to” primer for life sciences companies on applying end-to-end evidence strategies in demonstrating product value.

The Boston biotech cluster proved an ideal setting for Pharm Exec's recent annual Editorial Advisory Board meeting, with the prevailing message that even the best environments for innovation require constant nurturing.

Policymakers seek to limit prescribing while also encouraging innovative R&D.

while France remains a global force in the pharmaceutical, medical device, and vaccines fields-and continues to tout a solid manufacturing base and re-exportation culture-questions are arising over the long- term sustainability of the country’s healthcare system and its traditionally generous public health provisions.

Click the title above to open the Pharmaceutical Executive May 2016 issue in an interactive PDF format.

Policymakers seek to limit prescribing while also encouraging innovative R&D.